The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. There has been no safety...
Hence then, the article about foresee pharmaceuticals receives the fourth positive recommendation from the dsmb to continue the casppian ph3 study for central precocious puberty cpp was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP) )
Also on site :
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’